---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-012259"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-01-14T23:59:59+00:00"
generated_at: "2026-05-16T10:30:47.234095+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Perspective Therapeutics updates corporate presentation with pipeline progress and 2026 data expectations

## Summary
- Lead programs VMT-α-NET (SSTR2+ NETs), VMT01 (MC1R melanoma), PSV359 (FAP-α) all in Phase 1/2a trials.
- Proprietary 212Pb-based radioligand platform and chelator designed for broader use; manufacturing underway.
- Phase 1/2 data expected across all three clinical programs in 2026.
- Preliminary anti-tumor activity observed for VMT01 at lower dose; well-tolerated safety profile.
- VMT-α-NET shows compelling anti-tumor activity and best-in-class safety; potential registration study at current dose.

## SEC filing metadata
- accession: 0001193125-26-012259
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526012259/0001193125-26-012259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526012259/catx-20260114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-012259
- JSON: https://secwatch.observer/filing/0001193125-26-012259.json
- Plain text: https://secwatch.observer/filing/0001193125-26-012259.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.